{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:19:15Z","timestamp":1793744355590,"version":"4.6.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers, no systematic pan-cancer analysis of TREM2 is available. Thus, we aimed to explore the prognostic value, and investigate the potential immunological functions, of TREM2 across 33 cancer types. Based on datasets from The Cancer Genome Atlas, and the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and Human Protein Atlas, we employed an array of bioinformatics methods to explore the potential oncogenic roles of TREM2, including analyzing the relationship between TREM2 and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration of different tumors. The results show that TREM2 is highly expressed in most cancers, but present at low levels in lung cancer. Further, TREM2 is positively or negatively associated with prognosis in different cancers. Additionally, TREM2 expression was associated with TMB and MSI in 12 cancer types, while in 20 types of cancer, there was a correlation between TREM2 expression and DNA methylation. Six tumors, including breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach adenocarcinoma, were screened out for further study, which demonstrated that TREM2 gene expression was negatively correlated with infiltration levels of most immune cells, but positively correlated with infiltration levels of M1 and M2 macrophages. Moreover, correlation with TREM2 expression differed according to T cell subtype. Our study reveals that TREM2 can function as a prognostic marker in various malignant tumors because of its role in tumorigenesis and tumor immunity.<\/jats:p>","DOI":"10.3389\/fimmu.2021.646523","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T18:39:09Z","timestamp":1613759949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":112,"title":["Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker"],"prefix":"10.3389","volume":"12","author":[{"given":"Xin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kechao","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","article-title":"SnapShot: TCGA-analyzed tumors","volume":"173","author":"Blum","year":"2018","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","article-title":"The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway","volume":"181","author":"Deczkowska","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13024-017-0197-5","article-title":"TREM2 in neurodegenerative diseases","volume":"12","author":"Jay","year":"2017","journal-title":"Mol Neurodegenerat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(18)30232-1","article-title":"The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders","volume":"17","author":"Carmona","year":"2018","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00356-8","article-title":"TREM2 marks tumor-associated macrophages","volume":"5","author":"Nakamura","year":"2020","journal-title":"Signal Transduct Targeted Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing Anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41389-018-0115-x","article-title":"TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K\/Akt\/\u03b2-catenin pathway","volume":"8","author":"Tang","year":"2019","journal-title":"Oncogenesis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E1315","DOI":"10.3390\/cancers11091315","article-title":"TREM2 acts as a tumor suppressor in colorectal carcinoma through Wnt1\/\u03b2-catenin and Erk signaling","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers."},{"key":"B13","doi-asserted-by":"publisher","first-page":"29620","DOI":"10.18632\/oncotarget.8813","article-title":"TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer","volume":"7","author":"Yao","year":"2016","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.026","article-title":"High TREM2 expression correlates with poor prognosis in gastric cancer","volume":"72","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3892\/ijo.2016.3740","article-title":"Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K\/Akt pathway","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-020-0174-y","article-title":"TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials","volume":"4","author":"Choucair","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102024","DOI":"10.1016\/j.ctrv.2020.102024","article-title":"MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma","volume":"86","author":"van Velzen","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"DNA methyltransferase inhibitors: catalysts for antitumour immune responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0179726","DOI":"10.1371\/journal.pone.0179726","article-title":"Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors","volume":"12","author":"Siemers","year":"2017","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.2004.07.151","article-title":"DNA methylation and cancer","volume":"22","author":"Das","year":"2004","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.18632\/oncotarget.6221","article-title":"Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/gutjnl-2019-319227","article-title":"TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms","volume":"1","author":"Esparza-Baquer","year":"2020","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e22054","DOI":"10.1200\/jco.2013.31.15_suppl.e22054","article-title":"Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion","volume":"31","author":"Yao","year":"2013","journal-title":"Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1798147","DOI":"10.1155\/2020\/1798147","article-title":"TREM-1 and TREM-2 expression on blood monocytes could help predict survival in high-grade glioma patients","volume":"2020","author":"Kluckova","year":"2020","journal-title":"Med Inflammat."},{"key":"B28","unstructured":"TREM2 siRNA inhibits cell proliferation of human liver cancer cell lines431828\n            ZhangS-L\n            ChenT-S\n            XiaoL\n            YeY\n            XiaW\n            ZhangH\n          Int J Clin Exp Pathol92016"},{"key":"B29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","article-title":"Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts","volume":"131","author":"Fumet","year":"2020","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","article-title":"Tumor mutation burden: leading immunotherapy to the era of precision medicine","volume":"36","author":"Steuer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","article-title":"Tumor mutation burden as a biomarker in resected non\u2013small-cell lung cancer","volume":"36","author":"Devarakonda","year":"2018","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1158\/1078-0432.CCR-19-1105","article-title":"Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM200001133420201","article-title":"Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer","volume":"342","author":"Gryfe","year":"2000","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1586\/1744666X.2015.1043893","article-title":"Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells","volume":"11","author":"Nguyen","year":"2015","journal-title":"Exp Rev Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18546-x","article-title":"A gene expression signature of TREM2 hi macrophages and \u03b3\u03b4 T cells predicts immunotherapy response","volume":"11","author":"Xiong","year":"2020","journal-title":"Nature Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1074\/jbc.M109.038398","article-title":"The linker for activation of B cells (LAB)\/non-T cell activation linker (NTAL) regulates triggering receptor expressed on myeloid cells (TREM)-2 signaling and macrophage inflammatory responses independently of the linker for activation of T cells","volume":"285","author":"Whittaker","year":"2010","journal-title":"J Biol Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1523\/JNEUROSCI.2459-16.2017","article-title":"TREM2 promotes microglial survival by activating Wnt\/\u03b2-catenin pathway","volume":"37","author":"Zheng","year":"2017","journal-title":"J Neurosci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.646523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T18:39:20Z","timestamp":1613759960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.646523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2021.646523"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.646523","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"article-number":"646523"}}